Home
About Us
Resources
Team
- Leadership Team
- Advisory Board
News
Contact

Contact us

DISCOVER MORE ABOUT BT-205 and BT-219

BRIDGE THERAPEUTICS

217 Country Club Park, Ste. 325, Birmingham, AL, 35213

T. 877-223-6949 | E. info@bridgerx.net

CONTACT US

If you would like to learn more about Bridge Therapeutics please use the contact form below.

All fields marked with * are required.

217 Country Club Park
Ste. 325
Birmingham, AL, 35213

T: 877-223-6949

Bridge Therapeutics, Inc. is a development-stage pharmaceutical company pursuing FDA approval of BT‑219, a superior form of buprenorphine-naloxone for opioid use disorder (OUD), and approval of BT-205, a patented drug combination for the treatment of chronic pain in opioid-experienced patients (U.S. Patent #8410092).

© Copyright Bridge Therapeutics 2023. Bridge Therapeutics is a registered trademark of Bridge Therapeutics Inc.
All product and company names are trademarks™ or registered® trademarks of their respective holders. Use of them does not imply any affiliation with or endorsement by them.